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Medical Genetics, University of British Columbia, Vancouver
Although neurofibromatosis 1 (NF1) is a relatively common autosomal dominant condition, information about its
effect on mortality is limited. We used Multiple-Cause Mortality Files, compiled from U.S. death certificates by the
National Center for Health Statistics, for 1983 through 1997. We identified 3,770 cases of presumed NF1 among
32,722,122 deaths in the United States, a frequency of 1/8,700, which is one-third to one-half the estimated
prevalence. Mean and median ages at death for persons with NF1 were 54.4 and 59 years, respectively, compared
with 70.1 and 74 years in the general population. Results of proportionate mortality ratio (PMR) analyses showed
that persons with NF1 were 34 times more likely ( , 95% confidence interval [CI] 30.8–38.0) to havePMRp 34.3
a malignant connective or other soft-tissue neoplasm listed on their death certificates than were persons without
NF1. Overall, persons with NF1 were 1.2 times more likely than expected ( , 95% CI 1.14–1.28) toPMRp 1.21
have a malignant neoplasm listed on their death certificates, but the PMR was 6.07 (95% CI 4.88–7.45) for persons
who died at 10–19 years of age and was 4.93 (95% CI 4.14–5.82) for those who died at 20–29 years of age.
Similarly, vascular disease was recorded more often than expected on death certificates of persons with NF1 who
died at !30 years of age ( , 95% CI 1.31–6.71 at age !10 years; , 95% CI 1.38–4.68 atPMRp 3.26 PMRp 2.68
age 10–19 years; and , 95% CI 1.46–3.32 at 20–29 years) but not in older persons. This studyPMRp 2.25
supports previous findings of decreased life expectancy for persons with NF1 and, within the limitations of death
certificates, provides population-based data about NF1 morbidity and mortality that are useful to clinicians caring
for patients with NF1.
Introduction
Neurofibromatosis 1 (NF1 [MIM 162200]) is a rela-
tively common autosomal dominant disorder, with a fre-
quency of 1/3,000–4,000 persons (Poyhonen et al. 2000;
Rasmussen and Friedman 2000). Cardinal features in-
clude multiple cafe´-au-lait spots, benign neurofibromas,
and Lisch nodules of the iris. Other common features
include learning disabilities, mild shortness of stature,
and skeletal abnormalities. An increased risk of malig-
nancy has also been observed in patients with NF1 and
may be related to the proposed tumor-suppressor role
of the NF1 gene (Shen et al. 1996).
Despite the high prevalence of NF1, information
about its effect on mortality is limited. Sørensen and
associates (1986) studied a cohort of 212 patients with
NF1 who had been identified 42 years earlier in Den-
mark. Because probands were identified through hos-
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pitals (and therefore may have been more severely af-
fected), the Sørensen group analyzed data on both
probands and affected relatives. Survival of people with
NF1 was significantly lower than that of the general
population, and more so in probands than in affected
relatives. Malignant neoplasms were significantly in-
creased, primarily in probands (Sørensen et al. 1986;
Neerup and Jensen et al. 1998).
A 12-year follow-up of 70 adult patients with NF1
(Zo¨ller et al. 1995) found a decrease in life expectancy
of ∼15 years. Malignancy was the cause of death for
more than half the patients, and hypertension was sig-
nificantly associated with mortality. A third study used
data from Japanese vital statistics for 1968–1992 on
605 deaths in which neurofibromatosis was listed as the
underlying cause of death. The mean age at death in
this study was 43 years (Imaizumi 1995). However, the
authors did not distinguish between persons with NF1
and neurofibromatosis 2 (NF2), and no data were avail-
able on causes of death other than neurofibromatosis.
In addition, because only case subjects in which neu-
rofibromatosis was listed as the underlying cause of
death were included, neurofibromatosis was believed to
be underascertained in this population (Imaizumi
1995).
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In the present investigation, we used data from U.S.
death certificates to study rates of NF1-associated
deaths. Our population-based study includes data on
13,700 deaths of people with NF1 during 1983–1997.
We used these data to examine mean and median ages
at death and the most common conditions associated
with death in persons with NF1 compared with the
general U.S. population.
Methods
We used the Multiple-Cause Mortality Files (MCMFs),
which are compiled from U.S. death certificates by the
National Center for Health Statistics (NCHS) of the
Centers for Disease Control and Prevention. MCMFs
include demographic and geographic information and
codes from the International Classification of Disease,
Ninth Revision (ICD9) for the underlying cause of death
and for as many as 20 conditions listed on the death
certificate as “other significant conditions” (Israel et al.
1986). The ICD9 coding system has been used for mor-
tality statistics since 1979; however, because of incom-
plete collection of death certificates for 1981 and 1982,
the NCHS partially replicated data for these years (Israel
et al. 1986). We were concerned about the effect of this
case duplication on our small subset of case subjectswith
neurofibromatosis, so we limited our study to 1983–
1997.
The codes in the MCMFs are in two formats: entity
axis and record axis. The entity-axis format provides a
separate code for each disease listed, whether it is an
underlying cause of death or a contributory condition.
The record-axis format uses linkage rules to combine
some listings of conditions on the death certificates. We
selected all cases listing the ICD9 code for “neurofibro-
matosis (von Recklinghausen’s disease)” (237.7) in the
record axis. This code may also include cases of the
much less common but generally more severe condi-
tion NF2. We therefore excluded case subjects with the
codes for “sensorineural deafness” (389.1), “benign
neoplasms of cranial nerves” (225.1), “benign neo-
plasms of cerebral meninges”(225.2), and “benign neo-
plasms of spinal meninges” (225.4) as more likely to
have NF2. For the remaining case subjects, we deter-
mined mean and median ages at death to approximate
the survival of persons with NF1 overall and by sex and
race. Race is classified as “white,” “black,” or “other”
in the MCMFs; however, given the small number of case
subjects of other races, we grouped subjects into two
racial categories, “white” and “other.” Because the dis-
tribution of age at death was skewed, a logarithmic
transformation was applied to these data to obtain the
geometric mean age at death and the associated 95%
confidence intervals (CIs). We used the nonparametric-
median-scores method to test the differences between
median age at death in various categories. Version 8.0
of the SAS program was used for all analyses.
To investigate the relation of NF1-associated deaths
to other medical conditions, we calculated the propor-
tionate mortality ratio (PMR) for deaths of personswith
NF1 for several conditions. The PMR was calculated
as the observed number of deaths among persons with
NF1 who also had a specific condition divided by the
expected number of deaths of all persons with the spe-
cific condition. The expected number of deaths asso-
ciated with a particular condition was calculated on the
basis of the proportion of death certificates in the U.S.
population listing that condition during 1983–1997,
adjusted for decedent’s age, sex, race, and death-cohort
(Hennekens 1987). Because the complete file containing
132 million deaths was too large for convenient com-
putation, we used a randomly selected subset containing
25% of U.S. deaths during 1983–1997 to calculate the
expected number of deaths for each condition. We cal-
culated 95% CIs by assuming that the number of deaths
associated with both NF1 and another medical condi-
tion was distributed as a Poisson variable (Ahlbom
1993). PMR enables determination of whether a specific
medical condition is more or less likely in deaths in
which NF1 is listed on the death certificate than in
deaths in the general population. If the medical con-
dition is more likely in persons with NF1, the PMR will
be 11; if the medical condition is less likely, the PMR
will be !1. We selected 90 conditions for PMR analysis,
because they are frequently listed as causes of death in
the general population or because of their known as-
sociation with NF1 morbidity or mortality (Sørensen et
al. 1986; Zo¨ller et al. 1995; McGaughran et al. 1999).
For selected conditions, we also evaluated PMRs by age
group at death (!10, 10–19, 20–29, 30–39, 40–49,
50–59, 60–69, or70 years). For this study, we defined
vascular disease as hypertensive disease (ICD9 401–
405), cerebrovascular disease (ICD9 430–438), or a dis-
ease of the arteries or arterioles (ICD9 440–449). This
range includes renal artery stenosis (ICD9 440.1) but
does not include heart disease, which we considered
separately. We defined “heart disease (adult)” as ische-
mic heart disease (ICD9 410–414), diseases of the pul-
monary circulation (ICD9 415–417), and other forms
of heart disease (ICD9 420–429).
Results
We identified 3,829 case subjects with the code for neu-
rofibromatosis listed on the death certificate. We ex-
cluded 59 case subjects as likely to have NF2. Of these,
24 cases were coded with “benign neoplasms of cranial
nerves” (225.1), 32 were coded with “benign neoplasms
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Table 1
Geometric Mean Age, at Death, of Persons with NF1 and of the
U.S. General Population, 1983–97
CATEGORY
NO. OF
DEATHS
MEAN AGE,
AT DEATH, OF
(years)
DIFFERENCE
BETWEEN
MEANS [95% CI]
(years)
Persons
with NF1
U.S.
Population
All 3,770 54.4 70.1 15.7 [15.0–16.3]
Males 1,874 52.7 66.4 13.7 [12.8–14.6]
Females 1,896 56.1 74.0 17.9 [17.1–18.7]
Whites 3,150 55.4 71.5 16.1 [15.4–16.7]
Other races 620 49.6 61.3 11.7 [ 9.7–13.4]
1983–87 1,183 54.9 69.2 14.3 [13.2–15.4]
1988–92 1,247 53.9 69.8 15.9 [14.8–17.0]
1993–97 1,340 54.5 71.0 16.5 [15.5–17.6]
of cerebral meninges”(225.2), and 3 were assigned both
these codes. No case subjects had been coded for neuro-
fibromatosis and “sensorineural deafness” (389.1) or
“benign neoplasms of spinal meninges” (225.4). The
mean and median ages at death of the excluded case
subjects were 40.1 and 32 years, respectively.
Among 32,722,122 deaths in the United States, 3,770
presumed NF1-associated deaths remained, a frequency
of NF1-associated death of 1/8,700 deaths. The mean
age at death of persons with NF1 was 15.7 years lower
than the mean age at death in the general population
(table 1). Although the mean age at death of females
with NF1 was 13 years higher than that of males with
NF1, the difference between the mean ages at death of
persons with NF1 and of the U.S. general population
was greater for females. The mean age at death of per-
sons of other races who had NF1 was earlier than that
of whites, but the difference between the mean ages at
death of persons with NF1 and of the general popu-
lation was greater for whites than for those of other
races. The difference between mean ages at death of
persons with NF1 and the general population increased
during each of the three 5-year periods studied.
The median age at death of persons with NF1 was
59 years, whereas the median age at death of the U.S.
population was 74 years (fig. 1). The median age at
death was decreased more, compared with the general
population, among females with NF1 than amongmales
with NF1. The median age at death of persons of other
races with NF1 was decreased more than that of whites
with NF1, compared with the general population. The
difference between median ages at death of NF1 case
subjects and of the general population increased during
each of the three 5-year periods studied.
Because we wondered whether the effect of NF1
mortality was restricted to younger patients, we also
evaluated the mean and median age at death of per-
sons who died at age 40 years. The mean age at
death of persons with NF1 who survived 40 years
was 65.6 years, whereas the mean age at death for
this subset of the U.S. population was 74.5. The me-
dian age at death of persons with NF1 who died at
age 40 years was 67 years, compared with 76 years
for the U.S. population.
Malignant neoplasms (all), vascular disease, cerebro-
vascular disease (a component of vascular disease), sco-
liosis, epilepsy, and mental retardation were reported
more frequently than expected on death certificates of
persons with NF1 (table 2). Diabetes mellitus and sui-
cide were reported much less often than expected on
death certificates of persons with NF1, and heart disease
(adult) and diseases of the arteries and arterioles were
reported slightly less often than expected.
Among NF1-associated deaths (table 3), malignant
neoplasms of connective and other soft tissue were re-
ported 34 times more frequently than expected, and
neoplasms of the brain were reported 5.5 times more
frequently than expected. Other neoplasms were less
likely to be listed on the death certificates of persons
with NF1 than on those of the general population, and
this decrease reached statistical significance for malig-
nant neoplasms of the lymphatic/hematopoietic sys-
tem, breast (in women), trachea/bronchus/lung, pan-
creas, large bowel, prostate, uterine cervix, and skin.
The PMR for all malignant neoplasms, excluding those
of connective and other soft tissue and brain, was sig-
nificantly !1 ( ; 95% CI 0.64–0.75).PMRp 0.69
Malignant neoplasms as a group occurred more fre-
quently than expected among case subjects !39 years
of age (table 4). When connective and other soft-tissue
and brain neoplasms were excluded from malignant
neoplasms, the PMR for other neoplasms was elevated
for persons who died at !20 years of age. The PMR for
myeloid leukemia was substantially increased for chil-
dren aged !10 years, but malignant neoplasms of the
lymphatic and hematopoietic system as a group were
reported significantly less often than expected among
persons with NF1 aged 20–49 years. Malignant neo-
plasms of connective and other soft tissue were listed
much more frequently than expected among persons
with NF1 at all ages, and the PMR was 150 for persons
who died at age 20–39 years. Malignant neoplasms of
the brain were reported more often on death certificates
of persons with NF1 at all ages !70 years.
Vascular disease was reported more often than ex-
pected among persons with NF1 who were aged !29
years, but not in those who were older. The pattern was
similar for cerebrovascular disease considered alone, but
the PMR for hypertensive disease increased only among
case subjects who died at 20–29 years of age, and the
PMR for diseases of the arteries and arterioles decreased
among case subjects aged 160 years.
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Figure 1 Median (in box) and 5th, 25th, 75th, and 95th percentiles of ages at death of persons with NF1 and of the U.S. general population,
for all subjects and by sex, race, and time period.
Discussion
Our finding that survival, as estimated by mean and
median age at death, is ∼15 years less than expected in
persons with NF1 is consistent with the results of pre-
viously reported smaller studies. Zo¨ller et al. (1995)
monitored 70 adults with NF1 for 12 years and esti-
mated that the mean length of life for persons with NF1
was ∼15 years shorter than expected. Inclusion of per-
sons with NF1 presenting in childhood probably would
have lowered the life expectancy even further (Zo¨ller et
al. 1995). The study by Imaizumi (1995) found that, in
a Japanese population, the mean age at neurofibroma-
tosis-associated death was 43 years, much lower than
that seen in our study. However, Imaizumi’s study in-
cluded only case subjects for whom“neurofibromatosis”
was listed as the underlying cause of death, whereas our
study included all case subjects for whom neurofibro-
matosis was mentioned anywhere on the death certificate
and excluded case subjects who were more likely to have
NF2 than NF1. Neurofibromatosis was likely to be sig-
nificantly underascertained in Imaizumi’s study, result-
ing in a larger proportion of severe cases than in ours.
Thus, our study population is more likely to be repre-
sentative of all people with NF1.
Examination of mean and median ages at death sug-
gests that survival of females with NF1 is more severely
affected than that of males, in comparison with pop-
ulation expectations. Results of the study by Zo¨ller et
al. (1995) also suggested that women with NF1 may be
more severely affected than men. In the study by
Sørensen et al. (1986), female probands had the lowest
survival rate, but the survival of female relatives with
neurofibromatosis was only slightly less than that of the
general population. Another possible explanation is that
NF1 is likely to be diagnosed earlier in females, and
thus NF1 may be listed more often on death certificates
of females with NF1 who die earlier. In support of this,
the frequency of deaths for which NF1 was listed on
the death certificate is somewhat greater among females
than among males (1/8,343 deaths for females vs. 1/
9,019 for males). Further study is needed to determine
whether NF1 affects survival more strongly in females
than in males.
Evaluating the effect of race on NF1mortality is more
difficult. When subjects are stratified according to race,
a comparison of mean age at death of persons with NF1
with mean age at death in the general population sug-
gests that whites may be more severely affected than
are other races; however, a comparison of median ages
at death suggests that other races are more severely af-
fected. When we compare mean and median ages at
death by time period, the effect of NF1 on mortality
appears to be increasing. However, these results could
be secondary to earlier ascertainment of NF1 cases in
more recent years.
The highest PMR in our study was for malignant
neoplasms of connective and other soft tissue, a cate-
gory that includes malignant tumors of the peripheral
nerve sheath. These results are consistent with the rarity
of such tumors in the general population, their poor
prognosis, and their greatly increased frequency among
persons with NF1 (Woodruff 1999; King et al. 2000).
This type of tumor was identified as a major cause of
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Table 2
Likelihood of Selected Medical Conditions Being Listed on NF1-Associated Death Certificates, 1983–97
CONDITION ICD9 CODE(S)
NO. OF CASES
PMR (95% CI)Observed Expected
Malignant neoplasms (all) 140–208 1,170 965 1.21 (1.14–1.28)
Heart disease (adult) 410–414, 415–417, 420–429 1,365 1,571 .87 (.82–.92)
Heart disease (congenital) 745–747 19 19.9 .95 (.57–1.49)
Vascular disease 401–405, 430–438, 440–447 658 597 1.10 (1.02–1.19)
Hypertensive disease 401–405 244 219 1.11 (.98–1.26)
Cerebrovascular disease 430–438 398 327 1.22 (1.10–1.34)
Diseases of arteries and arterioles 440–447 123 157 .78 (.65–.93)
Diabetes mellitus 250 64 239 .27 (.21–.34)
Curvature of spinea 737 66 2.72 24.3 (18.8–3.9)
Epilepsy 345 35 10.3 3.40 (2.37–4.73)
Mental retardation 317–319 43 9.00 4.78 (3.46–6.44)
Suicide E950–E959 7 137 .05 (.02–.11)
a Includes scoliosis and kyphosis.
death in previous studies as well. In the study by Zo¨ller
et al. (1995), 3 of the 22 patients who died during the
period of observation had soft-tissue sarcomas.
We also found a significantly increased PMR for ma-
lignant neoplasms of the brain. A significant excess of
brain tumors was also found in the study by Sørensen
et al. (1986). Of 212 patients with malignant tumors,
21 (10%) had tumors of the CNS; however, some of
these persons may have had NF2 (Zo¨ller et al. 1995).
A high proportion of brain tumors was also seen in a
follow-up study of NF1 patients who had been previ-
ously evaluated in a neurofibromatosis clinic (Airewele
et al. 2001).
Malignant neoplasms are a major cause of death in
people with NF1: ∼55% of the cohort studied by Zo¨ller
et al. (1995) died of a malignancy, a rate higher than
expected on the basis of data from a cancer registry
(Zo¨ller et al. 1995). Our study also shows an increased
PMR for malignancy among persons with NF1, but the
excess was seen only among subjects who died at !40
years of age. This increased PMR appears to result pri-
marily from brain tumors and malignant neoplasms of
connective and other soft tissue. When these types of
cancer are excluded, the PMR for malignant neoplasms
among persons with NF1 is lower than expected
( ; 95% CI 0.64–0.75).PMRp 0.69
The PMR for myeloid leukemia was significantly el-
evated among children with NF1 who died at !10 years
of age. This observation is consistent with the known
relation between juvenile chronic myelogenous leuke-
mia and NF1 and the age at which this malignancy
occurs (typically diagnosed at !4 years of age) (Hess et
al. 1996). Myeloid leukemia was no more frequent than
expected among persons who died with NF1 at other
ages.
A number of reports have described life-threatening
or fatal vascular abnormalities in young patients with
NF1. The most frequently described manifestations are
severe hypertension, usually associated with renal artery
stenosis, and cerebrovascular disease associated with
moyamoya disease (Sobata et al. 1988; Muhonen et al.
1991; Hattori et al. 1998; Kwong and Wong 1999; Fos-
sali et al. 2000). Zo¨ller and colleagues (1995) found
that hypertension was significantly associated with NF1
mortality in a series of 70 adult patients monitored for
12 years. PMR for vascular disease was slightly higher
than expected among persons with NF1 than among
others, and this effect was especially prominent among
persons who died at !29 years of age. Most of this
increase in the PMR appears to be related to cerebro-
vascular disease, rather than to hypertensive disease or
other diseases of the arteries or arterioles.
On the basis of our evaluation of PMRs by age group,
we concluded that the impact of NF1 on mortality from
vascular disease and malignancy appears to be focused
on persons aged !40 years. However, even among per-
sons with NF1 who survive to age 40, the mean and
median ages at death are decreased by ∼9 years when
compared with the overall U.S. population. This is in
contrast to the 15-year decrease observed among all
persons with NF1 and suggests that NF1 affects mor-
tality even at older ages, although less so than in earlier
years.
This study has several important strengths. The use
of MCMFs allows a population-based analysis and a
comparison with data from the general population. The
study is based on data from recent years, and data are
available on deaths of 3,770 people with NF1, many
more than all previous studies combined. In addition,
our study provides data on deaths at all ages, whereas
most previous studies have been limited to deaths
among adults.
Our study also has several important limitations.
First, the data are based on death certificates, which
Rasmussen et al.: Mortality in NF1 1115
Table 3
Likelihood of Selected Malignant Neoplasms Being Listed on NF1-Associated Death Certificates, 1983–97
NO. OF CASES
TYPE OF MALIGNANT NEOPLASM ICD9 CODE(S) Observed Expected PMR (95% CI)
Connective and other soft tissue 171.0–171.9 353 10.3 34.3 (30.8–38.0)
Brain 191.0–191.9 181 32.8 5.52 (4.74–6.38)
Lymphatic/hematopoietic system 200–208 69 113 .61 (.48–.77)
Myeloid leukemia 205.0–205.9 20 20.9 .96 (.58–1.48)
Female breast 174.0–174.9 79 120 .66 (.52–.82)
Trachea/bronchus/lung 162.0–162.9 132 236 .56 (.47–.66)
Stomach 151.0–151.9 22 23.5 .94 (.59–1.42)
Liver and intrahepatic bile ducts 155.0–155.9 11 16.1 .68 (.34–1.22)
Pancreas 157.0–157.9 24 39.4 .61 (.39–.91)
Colorectala 153.0–154.9 38 94.6 .40 (.28–.55)
Ovary 183.0 21 28.8 .73 (.45–1.11)
Prostate 185.0–185.9 16 42.6 .38 (.21–.61)
Cervix uteri 180.0–180.9 4 18.7 .21 (.06–.55)
Body (or unspecified part) of uterus 179.0–179.9, 182.0–182.9 11 12.0 .92 (.46–1.64)
Skin (malignant melanoma) 172.0–173.9 12 23.2 .52 (.27–.90)
All neoplasms, excluding connective and soft tissue and brain 140–208, excluding 171 and 191 638 922 .69 (.64–.75)
a Includes colon, rectum, rectosigmoid junction, and anus.
previous studies have demonstrated to be both incom-
plete and, in some instances, inaccurate (Sirken et al.
1987; Lloyd-Jones et al. 1998). The low PMR observed
for suicide may be related to this issue; physicians com-
pleting death certificates of persons who died of suicide
may be less likely to also list NF1. Second, ICD9 does
not allow for distinction between NF1 and NF2. We
excluded cases coded as neurofibromatosis that had fea-
tures more characteristic of NF2 than of NF1; but some
cases of NF2 probably have been included, and some
cases of NF1 may have been excluded from our study.
NF1 cases appear to be underascertained in our study
population. The proportion of death certificates listing
neurofibromatosis is one-third to one-half the estimated
population prevalence of NF1 (Poyhonen et al. 2000;
Rasmussen and Friedman 2000). This underascertain-
ment could introduce a critical bias if NF1 is more likely
to be listed on the death certificates of persons who had
severe disease or complications that are well known to
be associated with NF1.
In addition, the ICD9 coding system used for mor-
tality statistics is often not specific enough to provide
all the information needed for a study of this kind. This
limited our analysis of benign tumors; for example,
plexiform neurofibromas are designated under the code
215 (other benign neoplasm of connective and other
soft tissue), but this code may also include other tumors,
such as cutaneous neurofibromas, thereby making anal-
ysis of this category impossible.
Another limitation is that our analyses of PMR used
multiple comparisons, increasing the likelihood of dem-
onstrating a statistically significant association when
one may not exist (Rothman and Greenland 1998). We
initially selected 90 codes on which to perform PMR
analyses, and we subsequently performed additional
analyses on eight age groups. However, the codes were
not selected randomly, but focused instead on known
associations with NF1 and common causes of death in
the general population. It is reassuring that our PMR
analyses generally confirm associations that have been
previously well recognized in NF1.
Without information about the number of persons
with NF1 living in the United States during each year
of the study, we cannot be certain that our PMRs ac-
tually reflect altered disease-related survival among per-
sons with NF1. A PMR could be lower than expected
if competing causes of death eliminated patients who
would have developed a particular disease if they had
lived long enough (Kupper et al. 1978; Hennekens
1987). However, such effects would have to be differ-
ential to affect the PMR; that is, for competing causes
of death to produce a lower PMR, persons with NF1
who would have died from one condition later in life
would have to die from something else earlier, and per-
sons with NF1 who are unlikely to die from that con-
dition later in life would rarely die from these alternative
causes earlier.
Because the PMR is a ratio, an increase in one cause
of death results in a decrease in all other causes (De-
coufle et al. 1980). The PMR could therefore be reduced
if the rate of a particular condition is unchanged but
the death rate associated with other medical conditions
is greatly increased. The PMR calculation is based on
the assumption that the overall rate of death from all
causes is the same in the two groups being compared.
This is unlikely to be true in the comparison between
people with and people without NF1. To the extent that
death from all causes is more likely among people with
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NF1, the PMRs we calculated will underestimate the
true cause-specific standardized mortality ratio (Roman
et al. 1984). An alternative method that is not subject
to this limitation is the use of the standardizedmortality
odds ratio (SMOR) (Miettinen and Wang 1981) to an-
alyze death-certificate data. We also performed SMOR
analyses on these data, and the results were similar to
those reported here for PMR (data not shown).
In conclusion, on the basis of our analysis of data
from U.S. death certificates, persons with NF1 appear
to have a decrease in life expectancy of ∼15 years, com-
pared with the general population. However, because
NF1 may have been significantly underascertained in
our study population, our analysis may overestimate
the difference in life expectancy between persons with
NF1 and the general population. Certain kinds of ma-
lignancy (especially brain tumors and malignant neo-
plasms of connective and other soft tissues) appear to
occur more frequently than expected in people who die
with NF1, but other kinds of cancer do not. Such ma-
lignancies and vascular disease (especially cerebrovas-
cular disease) appear to contribute disproportionately
to mortality in children and young adults with NF1.
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